The U.S. Food and Drug Administration (FDA) has announced that it will significantly restrict the use of the diabetes drug rosiglitazone (brand name, Avandia) to patients with Type 2 diabetes who cannot control their diabetes on other medications. Their decision is in response to data that...
GlaxoSmithKline (NYSE and LSE: GSK) confirms that following a review of Avandia® (rosiglitazone maleate) by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), each agency has announced their individual regulatory decisions and the resulting actions. In the...
Patients aged at least 65 years who have diabetes type 2 and take Avandia (Rosiglitazone) have a higher risk of developing stroke, heart failure, and even dying compared to similar patients who take Actos (Pioglitazone), according to a new study published in JAMA (Journal of the American Medical...
Researchers claim that pharmaceutical company GlaxoSmithkline has tried to influence the debate on the safety of diabetes treatment drug Avandia, also known as rosiglitazone, which the company manufactures. A new study claims that more than nine out of ten scientists who backed the drug had...